RecruitingPhase 3NCT07369154

52-week Open Label Safety-Tolerability Study

A 52 Week, Open Label Safety and Tolerability Study of LB-102 in Adult Patients With Schizophrenia

Sponsor

LB Pharmaceuticals Inc.

Enrollment

900 participants

Start Date

Apr 23, 2026

Study Type

INTERVENTIONAL

Conditions

Schizophrenia

Summary

Phase 3, open label, multicenter study designed to assess the long term safety and tolerability of LB-102 for the treatment of adult patients with stable schizophrenia

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called LB-102 for people with schizophrenia. The study is currently recruiting participants at 23 locations. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLB-102

LB-102 flexible dosing 50 mg - 100 mg

Locations(23)

Chandler Clinical Trials

Chandler, Arizona, United States

Pillar Clinical Research

Bentonville, Arkansas, United States

Pillar Clinical Research

Little Rock, Arkansas, United States

Woodland International Research Group

Little Rock, Arkansas, United States

Advanced Research Center

Anaheim, California, United States

Synapse Clinical Trials

Cerritos, California, United States

ProScience Research Group

Culver City, California, United States

CenExel

Culver City, California, United States

Synergy San Diego

San Diego, California, United States

CenExel

Hollywood, Florida, United States

Segal Trials

Miami Lakes, Florida, United States

Health Synergy Clinical Research

West Palm Beach, Florida, United States

CenExel

Atlanta, Georgia, United States

Accelerated Clinical Trial

Snellville, Georgia, United States

Pillar Clinical Research

Chicago, Illinois, United States

CenExel Gaithersburg

Gaithersburg, Maryland, United States

Arch Clinical Trials

St Louis, Missouri, United States

Redbird Research

Las Vegas, Nevada, United States

Neuro-Behavioral Clinical Research

New York, New York, United States

Neuro-Behavioral Clinical Research

Canton, Ohio, United States

Adams Clinical

Philadelphia, Pennsylvania, United States

Adams Clinical

DeSoto, Texas, United States

Pillar Clinical Research

Richardson, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07369154

Related Trials

Venous Tourniquet vs. Arterial Tourniquet for Seizure Monitoring in ECT

NCT075344751 location

Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia

NCT0736357713 locations

Emotional Eating, Sleep Quality, Mental State and Metabolic Syndrome

NCT074112221 location

A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia

NCT0688278556 locations

Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia

NCT072883336 locations